Pharmacotherapy for Triple-Negative Metastatic Breast Cancer: Therapeutic Updates Best Practices and Emerging Therapies
Cost: FreeView Offer chevron_right
Activity Description / Statement of Need:
In this online, self-learning activity:
Over a quarter million women and almost 2,700 men in the U.S. are diagnosed with breast cancer each year, and it is the second leading cause of cancer death in women. The prognosis associated with breast has improved in the last few decades due in larger part to earlier detection. Detection at the loco-regional stage is associated with a five-year overall survival (OS) rate of ≥ 85% in contrast to 27% for distant or metastatic breast cancer (mBC).
This activity has been designed to bring healthcare professionals’ knowledge of the rationale behind treatment of mTNBC up to date and to improve their competence and performance in treating it.
The following HCPs: medical oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with breast cancer.